The FDA clearance of Nevro1, a device that represents a significant advancement in SI joint fusion, is likely to positively impact Nevro Corp.'s stock price in the short term. This clearance not only enhances Nevro's product portfolio but also solidifies its position in the market for chronic pain treatment devices. The acquisition of Vyrsa Technologies and the integration of its products into Nevro's offerings further strengthen this outlook. Investors may view this regulatory approval as a sign of Nevro's continued innovation and growth potential in the medical device sector.